Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 136-147

  Giacchetti, Sylvie ^a   Perpoint, B ^a   Zidani, R ^a   Le Bail, N ^a   Faggiuolo, R ^a   Focan, C ^a   Chollet, P ^a   Llory, J F ^a   Letourneau, Y ^a   Coudert, B ^a   Bertheaut Cvitkovic, F ^a   Larregain Fournier, D ^a   Le Rol, A ^a   Walter, S ^a   Adam, R ^a   Misset, J L ^a   Levi F ^a  

^a DEBIOPHARM SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME;

EID: 0033989203     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.136     Document Type: Article

References (58)

1. Köhne-Wömpner CH, Schmoll HJ, Harstrick A, et al: Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials. Semin Oncol 19:105-125, 1992 (suppl 3)
2. Pinedo HM, Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
3. Scheithauer W, Rosen H, Kornek GB, et al: Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755, 1993
4. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685-696, 1986
5. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
6. Advanced Colorectal Cancer Meta-Analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960-969, 1994
7. Lokich J, Ahlgren J, Gullo J, et al: Prospective randomized comparison of continuous infusion of fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
8. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
9. De Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study. J Clin Oncol 2:808-815, 1997
10. Pendyala L, Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976, 1993
11. Tashiro T, Kawada Y, Sakurai Y, et al: Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane)platinum (II): New experimental data. Biomed Pharmacother 43:251-260, 1989
12. Mathé G, Kidani Y, Eriguchi M, et al: Oxalato-platinum or 1-OHP, a third generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother 43:237-250, 1989
13. Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303, 1990
14. Caussanel JP, Lévi F, Brienza S, et al: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82:1046-1050, 1990
15. Lévi F, Perpoint B, Garufi C, et al: Oxaliplatin activity against metastatic colorectal cancer: A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29:1280-1284, 1993
16. Machover D, Diaz-Rubio E, De Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996
17. Diaz-Rubio E, Sastre J, Zaniboni A, et al: Oxaliplatin as a single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 9:105-108, 1998
18. Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16:2739-2744, 1998
19. Lévi F: Chronopharmacology of anticancer agents, in Redfern PH, Lemmer B (eds): Handbook of Experimental Pharmacology: Physiology and Pharmacology of Biological Rhythms. Berlin, Germany, Springer-Verlag, 1997, pp 299-331
20. Smaaland R, Laerum OD, Lote K, et al: DNA synthesis in human bone marrow is circadian stage dependent. Blood 77:2603-2611, 1991
21. Antoch MP, Song EJ, Chang AM, et al: Functional identification of the mouse circadian Clock gene by transgenic BAC rescue. Cell 89:655-667, 1997
22. Boughattas N, Lévi F, Fournier C, et al: Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum (II) in mice. Cancer Res 49:3362-3368, 1989
23. Lévi F, Giacchetti S: Chronomodulation of chemotherapy against metastatic colorectal cancer, in Bleiberg H, Rougier P, Wilke HJ (eds): Management of Colorectal Cancer. London, United Kingdom, Martin Dunitz Publishers, 1998, pp 289-306
24. Lévi F, Misset JL, Brienza S, et al: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893-900, 1992
25. De Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
26. Lévi F, Zidani R, Vannetzel JM, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 86:1608-1617, 1994
27. Lévi F, Zidani R, Misset JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686, 1997
28. Gruia G, Giacchetti S, Deprés P, et al: Role of time of peak delivery of chronomodulated 5-fluorouracil (5-FU), 1-leucovorin (LV) and oxaliplatin (L-OHP) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 15:180, 1996 (abstr 372)
29. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organisation, 1979
30. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
31. Gehan EA: The determination of the number of patients required in a preliminary and a follow up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
33. Bertheault-Cvitkovic F, Jami A, Itzhaki M, et al: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 14:2950-2958, 1996
34. Lévi F, Zidani R, Brienza S, et al: A multicenter phase II trial of intensified chronotherapy with oxaliplatin (I-OHP), 5-fluorouracil (5-FU) and folinic acid (LV) in patients (pts) with previously untreated metastatic colorectal cancer (MCC). Cancer 85:2532-2540, 1999
35. Budd GT, Fleming TR, Bukowski RM, et al: 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: A randomised comparison - A Southwest Oncology Group Study. J Clin Oncol 5:272-277, 1987
36. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
37. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
38. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
39. Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
40. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989
41. O'Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer: A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63:1026-1030, 1989
42. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
43. Labianca R, Pancera G, Aitini E, et al: Folinic acid + 5-fluorouracil (5 FU) versus equidose 5FU in advanced colorectal cancer: Phase III study of "GISCAD." Ann Oncol 2:673-679, 1991
44. Di Costanzo F, Bartolucci R, Calabresi F, et al: Fluorouracilalone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research. Ann Oncol 3:371-376, 1992
45. Bobbio-Pallavicini E, Porta C, Moroni M, et al: Folinic acid does improve 5-fluorouracil activity in vivo: Results of a phase III study comparing 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 5:52-55, 1993
46. Scheithauer W, Depisch D, Kornek G, et al: Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer 73:1562-1568, 1994
47. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
48. Mustacchi G, Pavesi L, Milani S, et al: High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: Results of a randomized multicenter clinical trial. Anticancer Res 14:617-619, 1994
49. The Corfu-A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921-928, 1995
50. Recchia F, Nuzzio A, Lalli A, et al: Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. Am J Clin Oncol 19:301-304, 1996
51. Cunningham D, Zalcberg JR, Rath U, et al: Final results of a randomised trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7:961-965, 1996
52. Köhne CH, Schöffski P, Wilke H, et al: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16:418-426, 1998
53. Goldberg RM, Hatfield AK, Kahn M, et al: Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 15:3320-3329, 1997
54. Borner MM, Castiglione M, Bacchi M, et al: The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Ann Oncol 9:535-541, 1998
55. Cunningham D, Pyrhönen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
56. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 35:1407-1412, 1998
57. Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-522, 1996
58. Giacchetti S, Itzhaki M, Gruia G, et al: Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-flurouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663-669, 1999